Aim:

The present study was designed to investigate the expression of Polo-like kinase 1 (PLK1) and survivin in non-Hodgkin's lymphoma (NHL).

Methods:

The expression of PLK1 and survivin were detected with immunohistochemical techniques.

Results:

The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B-NHL and T-NHL, while survivin did not.

Conclusion:

PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.

References

1. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003; 17: 1948–60. | Article | PubMed | ChemPort |
2. Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays 2002; 24: 83–90. | Article | PubMed | ISI | ChemPort |
3. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–8. | Article | PubMed | ISI | ChemPort |
4. Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005; 24: 248–59. | Article | PubMed | ISI | ChemPort |
5. Dai W, Wang Q, Traganos F. Polo-like kinases and centrosome regulation. Oncogene 2002; 21: 6195–200. | Article | PubMed | ChemPort |
6. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006; 2: 608–17. | Article | PubMed | ChemPort |
7. Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol 2004; 164: 233–41. | Article | PubMed | ISI | ChemPort |
8. Zhou T, Aumais J P, Liu X, Yu-Lee LY, Erikson RL. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell 2003; 5: 127–38. | Article | PubMed | ISI | ChemPort |
9. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001; 40: 1117–23. | Article | PubMed | ISI | ChemPort |
10. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher W M, Ryan BM. Survivin: a promising tumor biomarker. Cancer Lett 2007; 249: 49–60. | Article | PubMed | ChemPort |
11. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006; 244: 164–71. | Article | PubMed | ChemPort |
12. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24: 287–91. | Article | PubMed | ISI | ChemPort |
13. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24: 267–76. | Article | PubMed | ISI | ChemPort |
14. Jaffe ES, Harris NL, Stein H. editors. Pathology and genetics of tumours of aematopoietic and lymphoid tissues. World Health Organization Classification of Tumours, Lyon, France: IARC Press; 2001.
15. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 815–21. | Article | PubMed | ISI | ChemPort |
16. Cheson BD. What is new in lymphoma? CA Cancer J Clin 2004; 54: 260–72. | PubMed |
17. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321–30. | Article | PubMed | ISI | ChemPort |
18. van Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004; 279: 36 841–54. | Article | ChemPort |
19. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997; 234: 397–405. | Article | PubMed | ISI | ChemPort |
20. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 543–9. | Article | PubMed | ISI | ChemPort |
21. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 2794–7. | PubMed | ISI | ChemPort |
22. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999; 15: 687–92. | PubMed | ISI | ChemPort |
23. Kanaji S, Saito H, Tsujitani S, Matsumoto S, Tatebe S, Kondo A, et al. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006; 70: 126–33. | Article | PubMed | ChemPort |
24. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001; 164: 41–9. | Article | PubMed | ISI | ChemPort |
25. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001; 169: 41–9. | Article | PubMed | ISI | ChemPort |
26. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 148–52. | Article | PubMed | ISI | ChemPort |
27. Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000; 196: 753–9. | PubMed | ISI | ChemPort |
28. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29: 354–8. | Article | PubMed | ISI |
29. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004; 60: 240–5. | Article | PubMed | ISI | ChemPort |
30. Ito Y, Miyoshi E, Sasaki N, Kakudo K, Yoshida H, Tomoda C, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004; 90: 414–8. | Article | PubMed | ISI | ChemPort |
31. Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89: 535–6. | Article | PubMed | ISI | ChemPort |
32. Wheatley SP, McNeish IA. Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 2005; 247: 35–88. | Article | PubMed | ChemPort |
33. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212–6. | Article | PubMed | ISI | ChemPort |
34. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581–9. | Article | PubMed | ISI | ChemPort |

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.